Empreu aquest identificador per citar o enllaçar aquest ítem:
http://hdl.handle.net/10609/146766
Títol: | Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection |
Autoria: | Prats, Anna Martínez Zalacaín, Ignacio Mothe, Beatriz Negredo, Eugenia Perez-Alvarez, Nuria Garolera, Maite Domènech Puigcerver, Sira Coll, Pep Meulbroek, Michael Chamorro, Anna Fumaz, Carmina R. Ferrer, Maria J. Clotet, Bonaventura Soriano-Mas, Carles Muñoz-Moreno, Jose A. |
Altres: | Hospital Universitari Germans Trias i Pujol Clínica Teknon Grupo Quirón-Salud Universitat Autònoma de Barcelona (UAB) Hospital Universitari de Bellvitge Universitat de Barcelona (UB) Universitat de Vic-Universitat Central de Catalunya (UVic-UCC) Universitat Politècnica de Catalunya (UPC) Instituto de Salud Carlos III Universitat Oberta de Catalunya (UOC) Projecte dels NOMS - Hispanosida |
Citació: | Prats, A., Martínez-Zalacaín, I., Mothe, B., Negredo, E., Pérez-Álvarez, N., Garolera, M., ... & Muñoz-Moreno, J. A. (2021). Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection. Scientific reports, 11(1), 1-9. |
Resum: | Integrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral regimens recommended for treatment of HIV infection. However, little is known about the impact of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial to evaluate the effects of INSTI-based antiretroviral therapy on comprehensive brain outcomes (cognitive, functional, and imaging) according to the time since HIV-1 acquisition. We recruited men living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date of HIV-1 acquisition (n = 12) and > 6 months since estimated date of HIV-1 acquisition (n = 15). We also recruited a group of matched seronegative individuals (n = 15). Assessments were performed at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive functioning was comparable between the arms. At week 48, we did not find cognitive differences between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of HIV-1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex over time, with expected negative repercussions for decision-making tasks. |
Paraules clau: | ansietat infeccions del sistema nervioso central neurociencia cognitiva depressió malalties infeccioses |
DOI: | https://doi.org/10.1038/s41598-021-90678-6 |
Tipus de document: | info:eu-repo/semantics/article |
Versió del document: | info:eu-repo/semantics/publishedVersion |
Data de publicació: | 28-mai-2021 |
Llicència de publicació: | http://creativecommons.org/licenses/by/4.0 |
Apareix a les col·leccions: | Articles Articles cientÍfics |
Arxius per aquest ítem:
Arxiu | Descripció | Mida | Format | |
---|---|---|---|---|
scientific reports-Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.pdf | Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection | 1,34 MB | Adobe PDF | Veure/Obrir |
Comparteix:
Els ítems del Repositori es troben protegits per copyright, amb tots els drets reservats, sempre i quan no s’indiqui el contrari.